KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Charles River Laboratories International (CRL) Accumulated Depreciation & Amortization (2016 - 2025)

Charles River Laboratories International has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $403.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.49% year-over-year to $403.3 million; the TTM value through Dec 2025 reached $403.3 million, up 11.49%, while the annual FY2025 figure was $403.3 million, 11.49% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $403.3 million at Charles River Laboratories International, up from $85.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $403.3 million in Q4 2025 and troughed at $85.2 million in Q3 2025.
  • A 5-year average of $226.4 million and a median of $259.6 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • On a YoY basis, Accumulated Depreciation & Amortization climbed as much as 41.01% in 2025 and fell as far as 67.2% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $265.5 million in 2021, then increased by 14.43% to $303.9 million in 2022, then rose by 3.37% to $314.1 million in 2023, then rose by 15.16% to $361.7 million in 2024, then grew by 11.49% to $403.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CRL at $403.3 million in Q4 2025, $85.2 million in Q3 2025, and $119.5 million in Q2 2025.